Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Arena Pharmaceuticals, Inc.    ARNA   US0400471027

SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Arena Pharmaceuticals, Inc. : Five Star Equities Issues New Research Reports on ARNA, DD, KR and VECO

06/17/2013 | 09:05am US/Eastern
Recommend:
0

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares hit a low of $7.70 Friday before settling to close at $7.78, a decrease of 6.71 percent. The stock traded in between $7.70 to $8.30 on volume of 8.97 million shares traded. Consumer Reports has recently advised their readers to ?skip? Arena?s weight loss drug, Belviq.

Get more information on Arena Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/ARNA

E I Du Pont De Nemours And Co (NYSE: DD) shares hit a low of $52.16 Friday before settling to close at $52.68, a decrease of 2.23 percent. The stock traded in between $52.16 to $53.70 on volume of 11.28 million shares traded. Jefferies Group currently has a ?hold? rating on the stock and has recently raised its price target on the company to $56.00 from $52.00.

Get more information on Du Pont and free access to the in-depth equity report at:
www.FiveStarEquities.com/DD

The Kroger Co. (NYSE: KR) hit a low of $34.67 Friday before settling to close at $34.79, a decrease of 0.77 percent. The stock traded in between $34.67 to $35.25 on volume of 2.46 million shares traded. Argus currently has a ?buy? rating on the stock and has recently raised its price target on the company to $40.00 from $34.00.

Get more information on Kroger and free access to the in-depth equity report at:
www.FiveStarEquities.com/KR

Veeco Instruments Inc. (NASDAQ: VECO) shares hit a low of $37.74 Friday before settling to close at $38.10, a decrease of 3.20 percent. The stock traded in between $37.74 and $39.04 on volume of 559,990 shares traded. UBS has reiterated it ?neutral? view on the company due to pricing pressure pricing pressure Veeco?s metal organic vapor deposition epitaxial systems.

Get more information on Veeco Instruments and free access to the in-depth equity report at:
www.FiveStarEquities.com/VECO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com


© Accesswire 2013
Recommend :
0
React to this article
Latest news on ARENA PHARMACEUTICALS, INC
08/11 ARENA PHARMACEUTICALS : Post-Earnings Review and Highlights - Arena Pharma
08/01 ARENA PHARMACEUTICALS : Provides Corporate Update and Reports Second Quarter 201..
07/31 ARENA PHARMACEUTICALS : Enters into Marketing and Supply Agreement for BELVIQ® l..
07/30 ARENA PHARMACEUTICALS : Eisai and Arena Pharmaceuticals Announce Publication of ..
07/29 ARENA PHARMACEUTICALS : Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcas..
07/29 ARENA PHARMACEUTICALS : Assigned Patent
07/25 ARENA PHARMACEUTICALS : to Host Corporate Update and Financial Results Conferenc..
07/23 ARENA PHARMACEUTICALS : Issued Patent for APD371 by United States Patent and Tra..
07/21 ARENA PHARMACEUTICALS : Enters into Marketing and Supply Agreement for BELVIQ® (..
07/16 ARENA PHARMACEUTICALS : Reports that Eisai Completes Planned Increase in Sales F..
Advertisement
Chart
Duration : Period :
Arena Pharmaceuticals, Inc Technical Analysis Chart | ARNA | US0400471027 | 4-Traders
Income Statement Evolution
Arena Pharmaceuticals, Inc : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF